Kringle Pharma,Inc.
4884 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 茨木市彩都あさぎ七丁目７番１５号彩都バイオインキュベータ２０７号
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company dedicated to advancing regenerative medicines through the development of innovative therapies based on recombinant human HGF (Hepatocyte Growth Factor). Focused on treating intractable and rare diseases, Kringle Pharma is conducting clinical trials to harness the protective and regenerative properties of HGF protein. The company's robust manufacturing capabilities ensure the production of high-quality pharmaceutical-grade HGF, positioning it as a leader in the field. By promoting the development of therapeutic agents aimed at addressing unmet medical needs, Kringle Pharma aims to transform the lives of patients globally, offering hope where few treatment options exist.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-16 09:00 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 364.6 KB | |
| 2025-05-12 08:41 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-05-12 08:40 |
Interim Report
半期報告書－第24期(2024/10/01－2025/09/30)
|
Japanese | 181.3 KB | |
| 2024-12-23 06:32 |
Inside Information Statement
臨時報告書
|
Japanese | 24.0 KB | |
| 2024-12-23 06:31 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-12-23 06:30 |
Annual Report
有価証券報告書－第23期(2023/10/01－2024/09/30)
|
Japanese | 2.2 MB | |
| 2024-12-23 06:30 |
Internal Control over Financial Reporting
内部統制報告書－第23期(2023/10/01－2024/09/30)
|
Japanese | 21.7 KB | |
| 2024-08-26 03:25 |
Inside Information Statement
臨時報告書
|
Japanese | 22.4 KB | |
| 2024-05-13 08:40 |
Quarterly Report
四半期報告書－第23期第2四半期(2024/01/01－2024/03/31)
|
Japanese | 179.6 KB | |
| 2024-05-13 08:40 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-02-09 07:41 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-02-09 07:40 |
Quarterly Report
四半期報告書－第23期第1四半期(2023/10/01－2023/12/31)
|
Japanese | 139.3 KB | |
| 2023-12-25 08:24 |
Inside Information Statement
臨時報告書
|
Japanese | 22.3 KB | |
| 2023-12-25 08:23 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2023-12-25 08:22 |
Internal Control over Financial Reporting
内部統制報告書－第22期(2022/10/01－2023/09/30)
|
Japanese | 21.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
GNI Group Ltd. | Japan | 2160 | |
|
Gour Medical | France | MLGML | |
|
Grifols S.A. | Spain | GRF | |
|
Grindeks | Latvia | GRD1R | |
|
Guerbet | France | GBT | |
|
Haemato AG | Germany | HAEK | |
|
Halychpharm | Ukraine | GFARM | |
|
Hamlet BioPharma AB | Sweden | HAMLET | |
|
Harm Reduction Group AB | Sweden | NOHARM | |
|
HEALIOS K.K. | Japan | 4593 |